Ropes & Gray advised Sanofi in a $10 million strategic investment in Stockholm-based Vicore Pharma Holding AB. Vicore plans to use the funding for its Phase 2b trial investigating the disease-modifying potential of buloxibutid for patients suffering from the lung disease idiopathic pulmonary fibrosis. The transaction was announced on Sept. 30.
The Ropes & Gray team included life sciences licensing associate Daniel Freshman and life sciences licensing partner Abigail Gregor.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.